The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials
Pooled result · MACEResult — go to the resultOdds ratio 0.82 95% CI 0.74–0.90Authors' conclusion
PCSK9i appear to be effective in reducing the risk of MACE and in improving lipid profiles of subjects with diabetes and dyslipidaemia.
Study context
- Population
- Patients with hypercholesterolaemia and DM
- Participants
- 20,651 patients8 randomized control trials (RCTs)
- Comparison
- PCSK9i vs placebo
- Outcome
- MACE
- Follow-up
- Mean 51 weeks
Methodological detailsPRISMA
- PRISMA
Pooled result
As reported in the abstract
Odds ratio
0.82
95% CI 0.74–0.90
By group
PCSK9ivs Placebo
OR 0.82 (95% CI 0.74–0.90)
Further pooled results
| Outcome | MD (%) (95% CI) | |
|---|---|---|
| Lipoprotein(a) and apolipoprotein BPCSK9ivs PlaceboLipoprotein(a) | −32.90 (−38.55 to −27.24) | |
| Lipoprotein(a) and apolipoprotein BPCSK9ivs PlaceboApolipoprotein B | −46.83 (−52.71 to --40.94) | |
| −100−50050Difference, % (linear scale) |
% change from baseline in LDL-C, high-density lipoprotein cholesterol (HDL-C), TG, non-HDL-C and total cholesterol (PCSK9 inhibitors vs control)
- LDL-C % change, MD
- −58.48%; 95% CI: −63.73 to −53.22%, P < 0.0001
- HDL-C % change, MD
- 5.21%; 95% CI: 3.26-7.17%
- TG % change, MD
- −14.59%; 95% CI: −19.42 to −9.76%
- Non-HDL-C % change, MD
- −48.84%; 95% CI: −54.54 to −43.14%
- Total cholesterol % change, MD
- −33.76%; 95% CI: −38.71 to −28.8%
Original publication
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. Published 27 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →